Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.

Tomefa E AsempaJoseph L KutiJeffrey C NascimentoSamuel J PopeEdward L SalernoPatrick J TroyDavid P Nicolau

Published in: The Journal of antimicrobial chemotherapy (2023)

The observed bronchopulmonary exposures of taniborbactam and cefepime can be employed to design optimal dosing regimens for clinical trials in patients with pneumonia.

Keyphrases

clinical trial
air pollution
phase ii
randomized controlled trial
childhood cancer
young adults
study protocol
intensive care unit